BackNuvalent Overview
Nuvalent Inc - Ordinary Shares - Class A

Nuvalent Target Price

Where could NUVL trade next? Consensus target price: $130.

Get informed when a big investor buys or sells

+ Follow

Share Price

$123.96

Average Target Price

$132.076.5% upside

13 analysts in the last 4 months

High: $189 | Low: $122.85

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-06-24Bernstein$1240% upsideOpen
2026-06-10GuggenheimBrad Canino$1240% upsideOpen
2026-06-10UBSDavid Dai$1240% upsideOpen
2026-06-09Wells FargoEva Fortea Verdejo$1240% upsideOpen
2026-06-09Truist Financial$1240% upsideOpen
2026-06-09Barclays$1240% upsideOpen
2026-06-09Robert W. Baird$122.850.9% downsideOpen
2026-06-09Stifel Nicolaus$1240% upsideOpen
2026-06-09Piper Sandler$1240% upsideOpen
2026-06-09Wedbush$1240% upsideOpen
2026-06-09H.C. Wainwright$1240% upsideOpen
2026-06-03Leerink PartnersAndrew Berens$16533.1% upsideOpen
2026-05-21Bernstein$18952.5% upsideOpen
2025-11-24Truist Financial$14012.9% upsideOpen
2025-11-17H.C. Wainwright$15525% upsideOpen
2025-11-17BarclaysEtzer Darout$15222.6% upsideOpen
2025-11-17Leerink Partners$14920.2% upsideOpen
2025-11-12Canaccord Genuity$1261.6% upsideOpen
2025-10-31Goldman Sachs$1203.2% downsideOpen
2025-10-31UBSDavid Dai$1326.5% upsideOpen
2025-10-27Piper SandlerKelsey Goodwin$1283.3% upsideOpen
2025-10-15Cantor FitzgeraldJosh Schimmer$1358.9% upsideOpen
2025-09-03Guggenheim$1221.6% downsideOpen
2025-09-02Raymond James$10515.3% downsideOpen
2025-06-24H.C. WainwrightSwayampakula Ramakanth$1304.9% upsideOpen
2024-11-13BMO CapitalEtzer Darout$1348.1% upsideOpen
2024-10-24UBSDavid Dai$10019.3% downsideOpen
2024-09-16GuggenheimKelsey Goodwin$10515.3% downsideOpen
2024-09-16Stifel NicolausBradley Canino$1358.9% upsideOpen
2024-09-16Raymond JamesChristopher Raymond$10019.3% downsideOpen
2024-07-10Stifel NicolausBradley Canino$1157.2% downsideOpen
2024-04-17JefferiesRoger Song$9721.7% downsideOpen
2024-04-01Leerink PartnersChristopher Liu$11011.3% downsideOpen

Nuvalent (NUVL) FAQ

Nuvalent (NUVL) currently reports a target price of $130. Use the charts on this page to explore Nuvalent's target price history and peer comparisons.

Analysts' average 12-month price target for Nuvalent is $130, about 6.5% upside from the current share price of $123.96. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $130, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Nuvalent, and consider following NUVL for alerts when major investors trade the stock.

Nuvalent is classified in the Healthcare sector. On target price, it currently shows $130. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NUVL with unrelated industries.